KREX World s only proteomics technology that produces full-length, correctly folded, functionally verified proteins

Transcription

1 THE functional proteomics company KREX World s only proteomics technology that produces full-length, correctly folded, functionally verified proteins

2 SENGENICS IS A CAMBRIDGE UNIVERSITY SPIN-OFF COMPANY 2 KREX platform originally invented by Dr Jonathan Blackburn Jonathan is the current CSO of Sengenics BA and DPhil Chemistry (Oxford University) HUPO Council Member HUPO Industrial Advisory Board Member Editorial advisory boards member of the Journal of Proteome Research Journal of Proteome Science & Computational Biology, and Expert Review of Proteomics

3 MAJOR CUSTOMERS AND COLLABORATORS 3

4 PATENTED AND UNIQUE KREX TECHNOLOGY FUNDAMENTAL PRINCIPLE 4 FUNDAMENTAL PRINCIPLE All proteins cloned in frame with BCCP, which acts as a folding marker and solubility enhancer Misfolded proteins washed away as they drive co-translations misfolding of BCCP, resulting in loss of function of BCCP Only correctly folded proteins are attached through binding between BCCP and streptavidin

5 TECHNOLOGY 5 Unique surface chemistry proteins behave as if in <FREE SOLUTION> KREX proteins are spotted onto surfaces that are coated with a layer of Polyethylene Glycol (PEG) gel, which serves several purposes: 1. Creates an aqueous environment 2. Retains protein stability 3. Prevents proteins from binding to the underlying glass surface 4. Retains localised conformational flexibility thus preserving the proteins 5. Prevents lateral diffusion of proteins across the array surface Streptavidin PEG layer

6 TECHNOLOGY 6 Single attachment point - consistent orientation 50 Angstrom spacer - protein projected in aqueous environment Efficiently biotinylated in most cells Very high binding affinity & specificity biotin / avidin (KD = M) other affinity tags: His tag / Ni-NTA (KD = 10-6 M) antigen / antibody (KD = 10-9 M)

7 TECHNOLOGY 7 No conventional purification Simultaneous purification and immobilisation - Surface Capture

8 SENGENICS ADDRESSES THE BIGGEST BOTTLENECK THAT TOP PHARMA HAS >98% of proteins were expressed solubly when using KREX whereas conventional approaches only give 48% success rate With KREX Without KREX

9 TECHNICAL PERFORMANCE 9 Immunome is a quantitative platform with picogram level sensitivity Serum dilutions: 1:1,000, 1:2,000, 1:4,000, 1:8,000, 1:16,000, 1:32,000, 1:64,000, 1:128,000 Serum antibody detection limit in the 10 pg/ml range Dynamic range is 4-5 orders of magnitude

10 CUSTOM CONTENT 10 Any number of proteins Any protein Any species Any format Fast turnaround Complete end-to-end capability Gene synthesis Cloning Expression Immobilisation on a variety of surfaces Functional assays Fast turnaround for custom projects

11 K REX EXPRESSED PROTEINS CAN THEN BE ATTACHED TO A WIDE VARIETY OF SURFACES 11 KREX Immunome microarrays KREX Glass micro-titre plates KREX SPR assays KREX Beads MASS SPEC ARRAY SCANNER PLATE READER BIACORE MASS SPEC

12 PROTEINS ON THE ARRAY ARE FUNCTIONAL 12 All assay-able proteins functionally validated on-array Kinases auto-phosphorylate Both auto-phosphorylation and kinase inhibition assays have been carried out on all the kinases on the Immunome array DNA binding proteins bind DNA Quantification in parallel of the effects of mutations and polymorphisms of p53 was measured by correlating Cy3 levels with the DNA binding function of p53 Methyltransferases Indirect functional assays

13 HOW WE MAKE MONEY 4 USE SYMPHONI DATABASE TO IDENTIFY TRUE POSITIVES 13 Symphoni is proprietary Sengenics database of Human autoantibody profiles 10,000s of Human autoantibody profiles Caucasian, Chinese, Indian, African and Malay samples True positive samples from cancers, autoimmune, metabolic and neurological disorders Biologically meaningful results as KREX-based proteins have linear and conformational epitopes can be used to: Improve specificity of autoantibody signatures by filtering out biomarkers for other diseases and aging can only be accessed by: Collaboration partners itap licensees

14 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 14 Applications of KREX Proteins at Different Stages of Drug Discovery Autoantibody biomarker discovery as potential therapeutic KREX Protein interactions with: Proteins DNA RNA Drugs Screen drug compounds against KREX protein of interest Assay activity, disruption or restoration of function as a result of adding or taking away co-factors SAR - link genetic mutations with KREX protein function e.g. Kinases or p53 Produce correctly folded, functional KREX proteins for antibody production Measure toxicity and or adverse reaction profiling Analyse effect on function of KREX proteins or by differential autoantibody profiles Patient stratification in terms of ADRs and response Analyse effect on function of KREX proteins or by differential autoantibody profiles Produce correctly folded, functional proteins for SPR or any other HTS assay

15 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 15 Cy3 Target deconvolution Incubate Immunome/kinase array with compounds tagged with fluorophore Multiple proteins in the Immunome and kinase array provides competitive landscape for the interaction of compounds Screened compounds to be tested against disease model for phenotypic profiling

16 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 16 CANCER CANCER AUTOIMMUNE NEURO INFECTIONS Immunotherapy Develop new diagnostic tests using Autoantibodies as biomarkers Discovery actual therapeutic Autoantibodies 1 Apply sample 2 - Auto-antibodies interact 3 Incubate with secondary ab, wash, scan

17 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 17 High-throughput screening of drug compounds Incubate kinome array with drug compounds conjugated to fluorophore Scan to detect signals Cy3 Cy3 Cy3

18 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 18 Identify novel small molecule modulators Incubate array with small molecule modulators Incubate array with protein substrate and determine protein kinetics with or without small molecule modulators Cy3 Cy3 Cy3

19 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 19 Compound selectivity Incubate array with labelled analog in a competitive displacement assay with unlabeled compounds (i.e. don t need to have a labelled competitor present) Quantify inhibition of enzymatic turnover by mass spectrometry at each location on the array Varying concentrations can be used to observe selectivity/affinity of compounds to kinases on the array

20 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 20 Affinity Profiling Assess affinity of drug compounds on various proteins/protein variants. Incubate array with varying concentrations of drug compounds Determine dissociation constant (Kd) of drug compound relative to protein of interest

21 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 21 Screening kinase mutants Incubate kinome array (containing both wild type and mutant kinases) with cy3-conjugated small molecules/compounds Ideal to establish structure-function relationships that would be helpful for molecular modelling to design new drugs Cy3 Cy3 Cy3

22 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 22 MDM2p/His ratio 1.2 p53 array probed with Cy3-labelled MDM Use custom KREX Proteins and 0.2 assays to discover anything that interacts with ANY protein Characterise protein interaction pathways Model viral antigen:host receptor interactions Characterise efficacy of antibody-based vaccines or drugs as disruptors PROTEIN DNA 0 wt W23A W23G R72P P82L M133T Q136X C141Y P151S P152L G154V R175H E180K R181C R181H H193R R196X R209X R213X P219S Y220C S227T H233N H233D N235D N235S S241F G245C G245S G245D R248W R248Q I251M L252P T256I L257Q E258K L265P V272L R273C R273H P278L R280K E286A R306X R306P G325V R337C L344P S392A DRUG ANTIBODY

23 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 23 Use custom KREX Proteins and assays to discover anything that interacts with ANY protein Identify interactors or disruptors Identify function restoration compounds Truly comparative and competitive n:n, rather than 1:n, or 1:1 interactions Proteins correctly folded so conformational and linear epitopes preserved Immunome array almost mirrors a SYSTEMS like approach Sensitivity very high, only single digit picomole quantities of protein or antibody required Enable analysis of transient interactions Enable analysis of interactions over time

24 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 24 DMSO Staurosporine Iressa Tarceva Gleevec Predictive toxicology On-chip phosphorylation assays demonstrate functionality of arrayed kinases This example demonstrates that human kinases on the array are present as homodimers (required for catalytic activity, as evidence by autophosphorylation in the presence of )

25 Target ID and Validation HTS Lead gen and selection Pre-clinical drug interactions Clinical trials 25 ADVERSE DRUG REACTIONS Predict ADRs based on global Autoantibody response Stratify patients in terms of responders and non-responders Pre-treatment and post-treatment stratification

26 SUMMARY 26 Immunome protein array: unique platform proteins are correctly folded and functional with 98% success rate can be customised for additional proteins in various expression systems Autoantibodies: are produced years before symptoms or other detectable biomarkers can be used as powerful biomarkers for early diagnosis have enormous potential as therapeutic drugs Immunome pharmaceutical applications include: monitoring ADRs predictive toxicology - drug effects on kinase and methyltransferase activity New developments in the pipeline include: on-chip PTMs on-chip protein complexes on-chip MHC I/II T-cells assays

27 THE functional proteomics company Sengenics UK Ltd. Registered in England and Wales no: Sengenics Corporation Pte Ltd. Registered in Singapore : no D finance@sengenics.com Tel: +44 (0) WWW. SENGENICS. COM